Skip to main content
SpringerLink
Log in

Dexfenfluramine

Its Place in Weight Control

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Dexfenfluramine, the dextrostereoisomer of fenfluramine, is a pure serotonin (5-hydroxytryptamine) agonist, apparently devoid of any additional antidopaminergic or sympathomimetic effects. The drug is approximately twice as effective as its racemic predecessor in reducing food intake in animals, and at a dose of 30 mg/day dexfenfluramine substantially modifies eating behaviour in man. Thus, a reduction in the motivation to eat and fewer snacking episodes were seen in volunteers treated with the drug, while total caloric and carbohydrate (but not protein) intakes were reduced in obese carbohydrate cravers. In clinical studies in obesity, dexfenfluramine combined with dietary support has produced mean weight reductions superior to those achieved with placebo over 3-month treatment periods. Importantly, the drug appears to maintain its weight-reducing effects for at least 12 months, without serious adverse effects.

Dexfenfluramine appears to possess many of the properties of an ‘ideal’ pharmacotherapeutic agent for obesity. However, further long term clinical studies are required to confirm the promising efficacy and safety data obtained to date, and to further define the most appropriate indications for its use. Ideally, the drug should be used as adjunctive treatment in the clinical management of more severe cases of obesity, which are refractory to simpler supportive measures such as dietary or psychological counselling.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Björntop P. The prevalence of obesity: complications related to the distribution of body fat. In Bender AE, Brookes LJ (Eds) Body weight control: the physiology, clinical treatment and prevention of obesity, pp. 72–80, Churchill Livingstone, Edinburgh, 1987

    Google Scholar 

  • Blundell JE, Hill AJ. On the mechanism of action of dexfenfluramine: effect of alliesthesia and appetite motivation in lean and obese subjects. Clinical Neuropharmacology 11(Suppl. 1): S121–S134, 1988

    PubMed  Google Scholar 

  • Borsini F, Bendotti C, Alleoti A, Samanin R, Garattini S. d-Fenfluramine and d-norfenfluramine reduce food intake by acting on different serotonin mechanisms in the rat brain. Pharmacological Research Communications 14: 671–678, 1982

    Article  PubMed  CAS  Google Scholar 

  • Borsini F, Bendotti C, Samanin R. Salbutamol, d-amphetamine and d-fenfluramine reduce sucrose intake in freely feeding rats by acting on different neurochemical mechanisms. International Journal of Obesity 9: 277–283, 1985

    PubMed  CAS  Google Scholar 

  • Bray GA. To treat or not to treat — that is the question. In Bray G (Ed.) Recent advances in obesity research II, pp. 248–265, Newman, London, 1978

    Google Scholar 

  • Carruba MO, Ricciardi S, Spano P, Mantegazza P. Dopaminergic and serotoninergic agents differentially antagonise insulin- and 2-DG-induced hyperphagia. Life Sciences 36: 1739–1749, 1985

    Article  PubMed  CAS  Google Scholar 

  • Enzi G, Crepaldi G, Inelmen EM, Bruni R, Baggio B. Efficacy and safety of dexfenfluramine in obese patients: a multicenter study. Clinical Neuropharmacology 11(Suppl. 1): S173–S178, 1988

    PubMed  Google Scholar 

  • Even P, Nicolaidis S. Metabolic mechanism of the anorectic and leptogenic effects of the serotonin agonist fenfluramine. Appetite 7 (Suppl.): 141–163, 1986

    Article  PubMed  CAS  Google Scholar 

  • Finer N, Craddock D, Lavielle R, Keen H. Dextrofenfluramine in the treatment of refractory obesity. Current Therapeutic Research 38: 847–854, 1985

    Google Scholar 

  • Finer N, Craddock D, Lavielle R, Keen H. Prolonged weight loss with dexfenfluramine treatment in obese patients. Diabete et Metabolisme 13: 598–602, 1987

    PubMed  CAS  Google Scholar 

  • Garattini S. Effects of d-fenfluramine on eating disorders. In Ferrari E, Brambilla F (Eds) Disorders of eating behaviour: a psychoneuroendocrine approach (Advances in the biosciences vol. 60), pp. 327–341, Pergamon Press, Oxford, 1986

    Google Scholar 

  • Garattini S, Bizzi A, Caccia S, Mennini T, Samanin R. Progress in assessing the role of serotonin in the control of food intake. Clinical Neuropharmacology 11(Suppl. 1): S8–S32, 1988

    PubMed  CAS  Google Scholar 

  • Garattini S, Mennini T, Bendotti C, Invernizzi R, Samanin R. Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system. Appetite 7 (Suppl.): 15–38, 1986

    Article  PubMed  CAS  Google Scholar 

  • Garattini S, Mennini T, Samanin R. From fenfluramine to d-fenfluramine: specificity and potency of the effects on the serotoninergic system and food intake. In Wurtman JJ, Wurtman RJ (Eds) Human obesity. Annals of the New York Academy of Sciences 499: 156–166, 1987

    Google Scholar 

  • Garattini S, Samanin R. d-Fenfluramine and salbutamol: two drugs causing anorexia through different neurochemical mechanisms. International Journal of Obesity 8(Suppl. 1): 151–157, 1984

    PubMed  CAS  Google Scholar 

  • Geelen MJH. Effects of fenfluramine on hepatic intermediary metabolism. Biochemical Pharmacology 32: 3321–3324, 1983

    Article  PubMed  CAS  Google Scholar 

  • Guy-Grand BJP. Place of dexfenfluramine in the management of obesity. Clinical Neuropharmacology 11(Suppl. I): S216–S223, 1988

    PubMed  Google Scholar 

  • Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, et al. International trial of long-term dexfenfluramine in obesity. Lancet 2: 1142–1145, 1989

    Article  PubMed  CAS  Google Scholar 

  • Hill AJ, Blundell JE. Model system for investigating the actions of anorectic drugs: effect of d-fenfluramine on food intake, nutrient selection, preferences, meal patterns, hunger and satiety in healthy human subjects. In Ferrari E, Brambilla A (Eds) Disorders of eating behaviour: a psychoneuroendocrine approach (Advances in the biosciences, vol. 60), pp. 377–389, Pergamon Press, Oxford, 1986

    Google Scholar 

  • Hirsh JA, Wurtman J. Effects of d or 1 isomers of fenfluramine and norfenfluramine on food choice by rats. In Garattini S, Samanin R (Eds) Anorectic agents: mechanisms of action and tolerance, pp. 159–168, Raven Press, New York, 1981

    Google Scholar 

  • Hoebel BG, Hernandez L, McClelland RC, Schwartz D. Dexfenfluramine and feeding reward. Clinical Neuropharmacology 11(Suppl. 1): S72–S85, 1988

    PubMed  CAS  Google Scholar 

  • Le Douarec VC, Schmitt H, Laubie M. Etude pharmacologique de la fenfluramine et de ses isomères optiques. Archives Internationales de Pharmacodynamie et de Thérapie 161: 206–232, 1966

    PubMed  Google Scholar 

  • Leibowitz SF, Weiss GF, Shor-Posner G. Hypothalamic serotonin: pharmacological, biochemical, and behavioural analyses of its feeding-suppressive action. Clinical Neuropharmacology 11(Suppl. 1): S51–S71, 1988

    PubMed  CAS  Google Scholar 

  • Levitsky DA, Schuster JA, Stallone D, Strupp BJ. Modulation of the thermic effect of food by fenfluramine. International Journal of Obesity 10: 169–173, 1986

    PubMed  CAS  Google Scholar 

  • Levitsky DA, Stallone D. Enhancement of the thermic effect of food by d-fenfluramine. Clinical Neuropharmacology 11(Suppl. 1): S90–S92, 1988

    PubMed  CAS  Google Scholar 

  • O’Rourke D, Wurtman J, Brzezinski A, Abou-Nader T, Marchant P, et al. Treatment of seasonal affective disorder with d-fenfluramine. In Wurtman JJ, Wurtman RJ, (Eds) Human obesity. Annals of the New York Academy of Sciences 499: 329–330, 1987

    Google Scholar 

  • Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 10: 241–323, 1975

    Article  PubMed  CAS  Google Scholar 

  • Rowland NE, Carlton J. Dexfenfluramine: effects on food intake in various animal models. Clinical Neuropharmacology 11(Suppl. 1): S33–S50, 1988

    PubMed  CAS  Google Scholar 

  • Russell GFM, Checkley AS, Feldman J, Eisler I. A controlled trial of d-fenfluramine in bulimia nervosa. Clinical Neuropharmacology 11(Suppl. 1): S146–S159, 1988

    PubMed  Google Scholar 

  • Silverstone T, Goodall E. The efficacy and acceptability of d-fenfluramine (Isomeride) in neuroleptic induced obesity. In Ferrari E, Brambilla F (Eds) Disorders of eating behaviour: a psychoneuroendocrine approach (Advances in the biosciences, vol. 60), pp. 361–366, Pergamon Press, Oxford, 1986

    Google Scholar 

  • Stunkard AJ. Behavioural treatment of obesity: the first ten years. In Bray G (Ed.) Recent advances in obesity research II, pp. 205–306, Newman, London, 1978

    Google Scholar 

  • Stunkard AJ. Anorectic agents lower a body weight set point. Life Sciences 30: 2043–2055, 1982

    Article  PubMed  CAS  Google Scholar 

  • Stunkard AJ, MacLaren Hume M. The result of treatment for obesity. Archives of Nutritional Medicine 103: 79–84, 1959

    Article  CAS  Google Scholar 

  • Turner P. Peripheral mechanism of action of fenfluramine. Current Medical Research and Opinion 6(Suppl. 1): 101–105, 1979

    Article  CAS  Google Scholar 

  • Turner P. Human implications from animal experiments — lessons from dexfenfluramine. Clinical Neuropharmacology 11(Suppl. 1): S113–S120, 1988

    PubMed  Google Scholar 

  • Turner P, Bichi LA, Slusarczyk H, Franklin CS. The peripheral actions of antiobesity drugs. International Journal of Obesity 6: 411–415, 1982

    PubMed  CAS  Google Scholar 

  • Veldhoven PV, Declerq PE, Debeer LJ, Mannderto GP. Effects of benfluorex and fenofibrate treatment on mitochondrial and peroxisomal marker enzymes in rat liver. Biochemical Pharmacology 33: 1153–1155, 1984

    Article  PubMed  Google Scholar 

  • Wurtman JJ, Wurtman RJ. d-Fenfluramine selectively decreases carbohydrate but not protein intake in obese subjects. International Journal of Obesity 8(Suppl. 1): 79–84, 1984

    PubMed  Google Scholar 

  • Wurtman JJ, Wurtman RJ, Mark S, Tsay R, Gilbert W, et al. d-Fenfluramine selectively suppresses carbohydrate snacking by obese subjects. International Journal of Eating Disorders 4: 89–99, 1985

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, St Bartholomew’s Hospital, London, EC1A 7BE, UK

    Paul Turner

Authors
  1. Paul Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turner, P. Dexfenfluramine. Drugs 39 (Suppl 3), 53–62 (1990). https://doi.org/10.2165/00003495-199000393-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199000393-00007

Keywords

Search

Navigation